Elstar Therapeutics Closes $39M Series A Financing

Elstar Therapeutics, a Cambridge, Mass.-based precision cancer immunotherapy company, closed a $39M Series A financing.

Founding backer Apple Tree Partners made the investment.

The funds will be used to expand its growing pipeline and progress several early stage molecules towards the clinic.

Led by Steve Arkinstall, D.Phil., President and Chief Executive Officer, Andreas Loew, Ph.D., founder and Chief Scientific Officer, Peter Williams, Chief Business Officer, and John Herrmann, Ph.D., Chief Strategy Officer and EVP, Oncology, Elstar has developed the Universal Targeted Immunotherapy (UniTI™) platform, which allows the rapid generation of multi-functional antibody-based molecules that enable patients to harness their own immune system to fight cancer.



Join the discussion